CAPA E LOMBADA - Arca - Fiocruz

109
Rader RA. Paucity of Biopharma Approvals Raises Alarm: Lower Numbers,
Novelty, and Economic Impact Indicate Problems (update this article). Gen
Eng Biotechnol News 2008; 28(6).
Radhakrishnan R, Walter LJ, Hruza A, Reichert P, Trotta PP, Nagabhushan TL et
al. Zinc mediated dimer of human interferon-α 2b revealed by X-ray
crystallography. Structure 1996; 4(12): 1453-1463.
Rai M, Padh H. Expression systems for production of heterologous proteins.
Curr Sci 2001; 8: 1121-1128.
Registro Sanitário de Produtos Biológicos. Instructivo SRPB-R: Solicitud para
el registro sanitário de productos ADN recombinante, anticuerpos
monoclonales y terapeuticos. [online]. Caracas, Venezuela; 2009 [capturado 28
jan 2009]. Disponível em: http://mail.inhrr.gov.ve:7474/pb/index.php
Reichert JM. Biopharmaceutical approvals in the US increase. Regul Aff J
2004; jul: 1-7.
Roche Brasil. Medicamentos biológicos. [online]. Rio de Janeiro, Brasil; 2007
[capturado 02 nov 2007]. Disponível em:
http://www.roche.com.br/NR/rdonlyres/27273F4A-1D0B-4FE4-9DD2-
8951FB89EE6E/6488/medicamentosbiologicos1.pdf
Rodrigues JAR, Moran PJS, Conceição GJA, Fardelone LC. Recent advances in
the biocatalytic asymmetric reduction of acetophenones and α,βunsaturated
carbonyl compounds. Food Technol Biotechnol 2004; 42(4): 295-
303.
Rosini N, Mousse D, Spada C, Treitinger A. Soroprevalence of HBsAg, anti-
HBc and anti-HCV in Southern Brazil, 1999-2001. Braz J Infect Dis 2003;
7:262-267.
Rudio FV. Introdução ao projeto de pesquisa científica. Petrópolis: Vozes;
1978.
Saavedra I, Quiñones L. Intercambiabilidad de medicamentos de origen
biológico (biofármacos): Consideraciones acerca de La aprobación de
formulaciones biosimilares (biogenéricos) en Chile. Rev Méd Chile 2006;
134: 1583-1588.